Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/004370AAV-BASED MODULATION OF GBA1 AND RELATED COMPOSITIONS AND USES THEREOF
WO 26.01.2023
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No PCT/US2022/073973 Applicant ASPEN NEUROSCIENCE, INC. Inventor BRATT-LEAL, Andres
The present disclosure provides adeno-associated vector (AAV)-based methods of increasing gene expression of a GBA1 in floor plate midbrain progenitor cells, determined dopamine (DA) neuron progenitor cells, and/or DA neurons, or glial cells, including those differentiated from pluripotent stem cells, and methods of lineage specific differentiation of the same. Also provided are compositions and uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease.
2.WO/2023/001256NANOPARTICLE AND USE THEREOF IN DETECTION OF CAR-POSITIVE EXPRESSION RATE
WO 26.01.2023
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/CN2022/107197 Applicant BEIJING ACROBIOSYSTEMS BIOTECHNOLOGY CO., LTD Inventor QIN, Lili
A nanoparticle and the use thereof in the detection of a CAR-positive expression rate. The nanoparticle comprises: (i) an enveloped virus-like particle (eVLP) skeleton protein and/or a functional fragment thereof; and (ii) a target protein and/or a functional fragment thereof. The nanoparticle can be used for detecting a CAR-positive expression rate, and can also be used for proving that a CAR can specifically bind to a target protein.
3.WO/2023/288334METHOD OF TREATING DRUG RESISTANT ESKAPE PATHOGENS USING THERAPEUTIC BACTERIOPHAGES
WO 19.01.2023
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
Appl.No PCT/US2022/073852 Applicant THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY Inventor FILIPPOV, Andrey
A method of improving an immunological response in a human subject suffering from a Pseudomonas aeruginosa in a wound comprising the step of: (i) administering one or more isolated and purified strains of Pseudomonas aeruginosa and one or more pharmaceutically acceptable carriers or adjuvants to the wounded area of the human subject, said genomic phages interacting with innate and adaptive immune system of the human subject, while providing biological protection and/or wound recovery or stimulation; and (ii) co-administering one or more additional genomic phages selected from genomic phages selected from Myoviridae, Podoviridae and Siphoviridae interacts and one or more pharmaceutically acceptable carriers or adjuvants to the wounded area of the human subject.
4.20230020806PHAGE CULTURING DEVICE, METHOD FOR PREPARING PHAGES, AND FILTRATION DEVICE FOR SAME
US 19.01.2023
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Appl.No 17785958 Applicant Kilian HENNES Inventor Kilian HENNES

A device and a method for clinically providing a preparation of autologous phages, namely, those that can verifiably be traced back to originating from a very specific person and preferably are also only intended for use in this one specific person includes a phage culturing device which is a fluid line system that is sealed off with respect to the outside environment The phages in the fluid line system obtained after at least one-time culturing are separated from bacteria by way of filtration, and preferably by way of tangential flow filtration. The phages separated by way of filtration are transferred into a collection vessel that is connected to the fluid line system and are preferably removed from the fluid line system, using the collection vessel, as a usable, preferably autologous preparation.

5.WO/2023/284879MODIFIED AAV CAPSID FOR GENE THERAPY AND METHODS THEREOF
WO 19.01.2023
Int.Class C07K 14/015
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
015Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
Appl.No PCT/CN2022/106118 Applicant HUIGENE THERAPEUTICS CO., LTD. Inventor SHI, Linyu
The invention described herein provide novel AAV capsids for improved tropism towards nervous tissues, eyes, and ears, for generating recombinant AAV viral vectors.
6.WO/2023/283745VIRAL VACCINE
WO 19.01.2023
Int.Class C12N 15/861
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
861Adenoviral vectors
Appl.No PCT/CA2022/051107 Applicant MCMASTER UNIVERSITY Inventor LICHTY, Brian
A trivalent transgene that encodes a viral surface glycoprotein component, a viral nucleoprotein component and a viral RNA polymerase component is provided. Vaccines incorporating the trivalent transgene are also provided, along with methods of vaccinating mammals to protect against viral infection.
7.WO/2023/285922ENGINEERED BACTERIOPHAGE T4 NANOPARTICLES AS A POTENTIAL TARGETED ACTIVATOR OF HIV-1 LATENCY IN CD4+ HUMAN T-CELLS
WO 19.01.2023
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/IB2022/056234 Applicant THE CATHOLIC UNIVERSITY OF AMERICA Inventor RAO, Venigalla B.
Described is an engineered viral particle programmed with T cell targeting specificity. The viral particles comprise: at least one viral vector, such as bacteriophage T4; and at least one CD4-binding protein displayed on the surface of the viral vector. Also described is a method of reactivate latent HIV-1 and cure patient with HIV-1 infection, using such an engineered viral particle.
8.WO/2023/287889BIOSENSOR FOR THE DETECTION OF SARS-COV-2 SPIKE GLYCOPROTEIN AND RELATED METHODS
WO 19.01.2023
Int.Class G01N 27/414
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
26by investigating electrochemical variables; by using electrolysis or electrophoresis
403Cells and electrode assemblies
414Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
Appl.No PCT/US2022/036972 Applicant CARBON HOLDINGS INTELLECTUAL PROPERTIES, LLC Inventor LINDEMANN, Garrett W.
An example biosensor includes a substrate, a graphene layer disposed on the substrate, and a binding site bonded to the graphene. The binding site includes an antibody configured to bind a SARS-CoV-2 spike glycoprotein. The biosensor can be configured to detect the SARS-CoV-2 spike protein in at least one of a saliva sample or a blood sample.
9.WO/2023/284635ONCOLYTIC VIRUS AND USE THEREOF
WO 19.01.2023
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
Appl.No PCT/CN2022/104525 Applicant JOINT BIOSCIENCES (SH) LTD. Inventor ZHOU, Guoqing
Provided is an oncolytic virus, comprising an M protein and a G protein. The M protein comprises amino acid substitutions at sites 51, 221, and 226 compared with the amino acid sequence as shown in SEQ ID NO: 1. The G protein comprises at least one amino acid substitution compared with the amino acid sequence as shown in SEQ ID NO: 2. Also provided are an oncolytic virus expression vector, a virus production cell for producing the oncolytic virus, and a pharmaceutical composition comprising the oncolytic virus, and a preparation method for the oncolytic virus, the oncolytic virus expression vector, the virus production cell, and/or the pharmaceutical composition, and the use thereof.
10.20230018934METHOD OF IN VIVO ADMINISTRATION OF THE CODING SEQUENCE OF THE SIRT6 GENE VIA ADENO-ASSOCIATED VIRUS
US 19.01.2023
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 17865688 Applicant GENFLOW BIOSCIENCES SRL Inventor Eric LEIRE

Methods for in vivo administration of the coding sequence of the sirt6 gene. In particular, methods that include the administration of adeno-associated virus vectors or recombinant adeno-associated virus vectors including the coding sequence of the sirt6 gene.